Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 30, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 30, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/31/17 - 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
3- V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and metabolic diseases, announced today that it will present data from its ongoing Phase 1 clinical study of TVB-2640 in solid tumor patients at the AACR annual meeting in Washington, D.C. The abstract "First in human study of the first-in-class
3/31/17 - 5 Stocks To Watch For March 31, 2017
BlackBerry shares rose 0.86 percent to $7.01 in after-hours trading. Akari Therapeutics PLC disclosed that the FDA has granted Fast Track designation for Coversin. Akari Therapeutics shares climbed 8.11 percent to $7.55 in the after-hours trading session. Analysts are expecting Sorl Auto Parts, Inc. to have earned $0.19 per share on revenue of $64.
3/31/17 - ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer [Palestine News Network]
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced Michael J. Yang has joined ACADIA as Executive Vice President and Chief Commercial Officer. Mr. Yang succeeds Terrence O. Moore, who has
3/31/17 - ACCUREXA INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Henry Brem, Director of the Neurosurgery Department at Johns Hopkins University. Henry Brem who built one of the largest brain tumor research and treatment centers in the world at Johns Hopkins University. Dr. Brem is a pioneer in the development of local drug delivery treatments, and invented and developed Gliadel which is a FDA approved, local
3/31/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Zileuton Extended Release Tablets, 600 mg
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Zileuton Extended Release Tablets, 600 mg.
3/31/17 - Aerpio Pharmaceuticals Raises $40 Million
By a News Reporter-Staff News Editor at Health& Medicine Week Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced the successful completion of its reverse merger transaction with Aerpio Therapeutics, Inc. and Aerpio Acquisition Corp., a wholly-owned subsidiary of
3/31/17 - AEZS One Step Closer, AKTX To Report Data In April, CBIO On The Move
LONDON- Aeterna Zentaris Inc. is gearing up to file a new drug application seeking approval of Macrilen for the evaluation of growth hormone deficiency in adults in the third quarter of this year. This compound carries orphan drug designation of the FDA for diagnosis of growth hormone deficiency in adults. Akari Therapeutics' investigational drug C
3/31/17 - After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers [Syrian Arab News Agency]
-Madison, Wis. Cellectar Biosciences, Inc., an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate CLR 131 in patients with multiple myeloma and other hematologic malignancies. Cellectar will receive approximately $2 million in a non-dilutive gran
3/31/17 - Agilent Technologies Receives 2017 Scientists' Choice Award for Best Webinar Series
By a News Reporter-Staff News Editor at Drug Week Agilent Technologies Inc. has received a 2017 Scientists' Choice Award- Best Webinar Series of the Year- for its Biopharmaceuticals Webinar Series titled Solutions in Biopharmaceutical Discovery and Development, which ran for 10 episodes over the course of 2016. "We were delighted to present Agil
3/31/17 - Akari Therapeutics Announces FDA Fast Track Designation For Coversin [Tehran Times (Iran)]
-Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug Administration has granted Fast Track designation for Coversin for treatment of paroxysmal nocturnal hemoglobinuria in patients who have polymorphisms conferring eculizumab resistance. Gur Roshwalb, Chief Executive Officer...
3/31/17 - Akari Therapeutics Reaches Double-Digits After FDA Ruling For Conversin
Akari Therapeutics PLC shares are trading higher by $3.40 at $10.40 in Friday's session.The catalyst for the rally is a report that the company has received FDA fast track designation for the Coversin. On Thursday, before the announcement, the stock added $0.33 from $6.65 to $6.98 on one of its biggest volume days in years. After a higher open, it
3/31/17 - Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
By a News Reporter-Staff News Editor at Drug Week Alkermes plc announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis. The company plans to submit a New Drug Application for ALKS 8700 for the treatment of RRMS to th
3/31/17 - Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases
By a News Reporter-Staff News Editor at Genomics& Genetics Weekly- Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc., a leading genome editing company, announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and...
3/31/17 - Amphastar Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President will be presenting at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 12:50 p.m. Eastern Time in New York, NY.. The Amphastar Pharmaceuticals logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but
3/31/17 - Amryt posts 1.35m sales as pipeline drugs advanced [Sudan Tribune]
Amryt Pharma, the orphan drug development company that was subject to a reverse takeover by former oil and gas group Fastnet last year, posted 1.35 million of sales last year. Amryt, led by chief executive Joe Wiley, secured exclusive rights in December to market US-based Aegerion Pharmaceuticals drug called Lojuxta, which is used to treat disorder
3/31/17 - Analyst Activity Cann Reiterates Hold on CytomX Therapeutics (NASDAQ:CTMX)
Analyst Ratings For CytomX Therapeutics (NASDAQ:CTMX) Today, Cann reiterated its Hold rating on CytomX Therapeutics (NASDAQ:CTMX). There are 1 sell rating, 2 hold ratings, 3 buy ratings on the stock. The current consensus rating on CytomX Therapeutics (NASDAQ:CTMX) is Hold (Score: 2.33) with a consensus target price of $28.00 per share, a potential
3/31/17 - Analyst Activity Jefferies Group LLC Reiterates Buy on Alder Biopharmaceuticals (NASDAQ:ALDR)
Analyst Ratings For Alder Biopharmaceuticals (NASDAQ:ALDR) Today, Jefferies Group LLC reiterated its Buy rating on Alder Biopharmaceuticals (NASDAQ:ALDR) with a price target of $43.00. There are 9 buy ratings on the stock. The current consensus rating on Alder Biopharmaceuticals (NASDAQ:ALDR) is Buy (Score: 3.00) with a consensus target price of $4
3/31/17 - Analyst Activity Stifel Nicolaus Reiterates Buy on Acorda Therapeutics (NASDAQ:ACOR)
Analyst Ratings For Acorda Therapeutics (NASDAQ:ACOR) Today, Stifel Nicolaus reiterated its Buy rating on Acorda Therapeutics (NASDAQ:ACOR) with a price target of $30.00. There are 3 hold ratings, 6 buy ratings on the stock. The current consensus rating on Acorda Therapeutics (NASDAQ:ACOR) is Buy (Score: 2.67) with a consensus target price of $33.8
3/31/17 - APTEVO THERAPEUTICS INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis together with the financial statements and the related notes to those statements included elsewhere in this report. The accompanying Management's Discussion and Analysis of Financial Condition and Results of Operations gives effect to the restatement adjustments made to the previously reported..
3/31/17 - argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
-Topline data from the study expected in second half of 2018- 31 March 2017 Breda, the Netherlands/ Ghent, Belgium- argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a Phas
3/31/17 - argenx Doses First Patient in ARGX-113 Study
Argenx announced the dosing of the first patient in a Phase II proof-of-concept study for ARGX-113 in patients with primary immune thrombocytopenia. As quoted in the press release:. The initiation of the second Phase II trial for our lead candidate, ARGX-113, is an important milestone for the company as it exemplifies the breadth of potential th
3/31/17 - As Health Care Debate Shifts, Senator Franken and Senate Colleagues Lead Milestone Effort to Bring Down Prescription Drug Prices
Jeff Merkley, D- Ore., issued the following news release:. In the wake of Congressional Republicans' failed attempt to rip health coverage away from millions of Americans, U.S. Senator Al Franken and a key group of Senate Democrats launched a major push to improve the Affordable Care Act by bringing down the skyrocketing price of prescription drugs
3/31/17 - As Health Care Debate Shifts, Senators Reed and Whitehouse Join New Effort to Bring Down Prescription Drug Prices
WASHINGTON, DC- In the wake of Congressional Republicans' failed attempt to rip health coverage away from millions of Americans, U.S. Senators Jack Reed and Sheldon Whitehouse have joined Al Franken and a key group of Senate Democrats to launch a major push to improve the Affordable Care Act by bringing down the skyrocketing price of prescription d
3/31/17 - Ascendis Pharma A/S Announces Updated Time for April 3 Conference Call to Review ENDO 2017 Data
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company has updated the time for its conference call and webcast on Monday, April 3 during ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florid
3/31/17 - AstraZeneca's potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe
Release date- 29032017- AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency has granted orphan designation to inebilizumab for the treatment of neuromyelitis optica spectrum disorder. Developed by MedImmune, inebilizumab is currently in Phase IIb clinical development for..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415